Impact of age and cytomegalovirus on CD8+ T-cell compartment remodeling after solid organ transplantation: A one-year follow-up study

2017 ◽  
Vol 95 ◽  
pp. 98-106 ◽  
Author(s):  
Sara Cantisán ◽  
Aurora Páez-Vega ◽  
Francisco Santos ◽  
Alberto Rodríguez-Benot ◽  
Rocío Aguado ◽  
...  
Keyword(s):  
T Cell ◽  
Organ Transplantation ◽  
Solid Organ Transplantation ◽  
Cd8 T Cell ◽  
Solid Organ ◽  
Cell Compartment ◽  
Follow Up Study ◽  
One Year

scholarly journals Monitoring of Human Cytomegalovirus-Specific CD4+and CD8+T-Cell Immunity in Patients Receiving Solid Organ Transplantation

2006 ◽  
Vol 6 (10) ◽  
pp. 2356-2364 ◽  
Author(s):  
G. Gerna ◽  
D. Lilleri ◽  
C. Fornara ◽  
G. Comolli ◽  
L. Lozza ◽  
...  
Keyword(s):  
T Cell ◽  
Organ Transplantation ◽  
Human Cytomegalovirus ◽  
Solid Organ Transplantation ◽  
Cd8 T Cell ◽  
T Cell Immunity ◽  
Solid Organ ◽  
Cell Immunity

Long Term Efficacy of Rituximab in B-Cell Post Transplantation Lymphoproliferative Disorders (B-PTLD): Update of the Multicenter, Open Label, Phase II Trial (M39037 TRIAL).

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 2764-2764
Author(s):  
Sylvain Choquet ◽  
Raoul Herbrecht ◽  
Anne-marie Stoppa ◽  
Peter Vandenberghe ◽  
Walter Feremans ◽  
...  
Keyword(s):  
Organ Transplantation ◽  
Prospective Trial ◽  
Solid Organ Transplantation ◽  
Treatment Modalities ◽  
Solid Organ ◽  
Open Label ◽  
Term Efficacy ◽  
One Year

Abstract Background: B-PTLD is a rare but severe complication observed after organ transplantation. There is no consensus on treatment modalities in this setting but Rituximab monotherapy has been presented as an effective and well tolerated treatment. Long term efficacy is unknown. Aim: We recently published results of the first prospective study on PTLD treatment, using four weekly injection of Rituximab in progressive or non responding tumours after immunosuppression diminution (Blood2006; 107; 3053–7). We present here update results up to 6 years after inclusion. Methods: From may 2000 to December 2001, 43 PTLD after solid organ transplantation have been enrolled in M39037, a franco-belgian multicentric prospective trial. The primary end point was day 80 response rate and one year results were also presented. Participating centres were contacted in order to obtain update data on surviving patients at one year, especially for their tumour status (complete response (CR), partial response (PR) or progressive disease (PD)), date of last information, eventual death and cause of death. Results: At one year, on 43 included patients, 26 were still alive, 12 in CR or Cru, one in PR, 10 in PD and two with insufficient information. At this time, update data are available on eight patients, six were in CR or Cru at one year and two in PD. Five patients died by organ failure (n=1), graft rejection (n=1), sudden death (n=2) or heart biopsy complication (n=1); all but one were in CR at this time. Three patients are still alive and in CR. No relapse has been diagnosed and median survival is 1188 days (with a median follow up of 1689 days for surviving patients). Final analysis on all patients will be presented at the ASH meeting. Conclusion: Rituximab in monotherapy seems to have a durable efficacy on PTLD after solid organ transplantation with a follow up of more than 4,5 years. Complete results will be presented at the ASH Meeting.

Approaches for monitoring of non virus-specific and virus-specific T-cell response in solid organ transplantation and their clinical applications

2015 ◽  
Vol 70 ◽  
pp. 109-119 ◽  
Author(s):  
Sandra A. Calarota ◽  
Judith H. Aberle ◽  
Elisabeth Puchhammer-Stöckl ◽  
Fausto Baldanti
Keyword(s):  
T Cell ◽  
Organ Transplantation ◽  
Cell Response ◽  
Solid Organ Transplantation ◽  
Clinical Applications ◽  
T Cell Response ◽  
Solid Organ

Bilateral sequential lung transplantation in Jehovah’s Witnesses

Perfusion ◽  
2020 ◽  
pp. 026765912093936
Author(s):  
Ernest G Chan ◽  
Matthew R Morrell ◽  
Patrick G Chan ◽  
Pablo G Sanchez
Keyword(s):  
Lung Transplantation ◽  
Organ Transplantation ◽  
Solid Organ Transplantation ◽  
Limited Resource ◽  
Solid Organ ◽  
Jehovah’S Witness ◽  
Jehovah's Witness ◽  
Long Term Follow Up

The ethical concerns of refusing lifesaving treatments after receiving an already limited resource such as a solid organ transplantation in a Jehovah’s Witness patient have been discussed in the literature. Many of these studies have concluded that with a multidisciplinary approach, solid organ transplantation is possible in the setting of Jehovah’s Witness patients. To date, there are no reported cases of bilateral sequential lung transplantation in the literature. We report two successful cases of bilateral sequential lung transplantation in Jehovah’s Witness patients with excellent long-term follow-up.

scholarly journals No Recurrence of Pneumocystis jirovecii Pneumonia after Solid Organ Transplantation Regardless of Secondary Prophylaxis

2012 ◽  
Vol 56 (11) ◽  
pp. 6041-6043 ◽  
Author(s):  
Tark Kim ◽  
Heungsup Sung ◽  
Yu-Mi Lee ◽  
Hyo-Lim Hong ◽  
Sung-Han Kim ◽  
...  
Keyword(s):  
Cohort Study ◽  
Organ Transplantation ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Solid Organ Transplantation ◽  
Secondary Prophylaxis ◽  
Pneumocystis Jirovecii Pneumonia ◽  
Solid Organ ◽  
Content Type

ABSTRACTThere are no data on the efficacy of secondary prophylaxis againstPneumocystispneumonia after solid organ transplantation. Therefore, we investigated the rate of recurrence ofPneumocystispneumonia after solid organ transplantation in a retrospective cohort study. Between 2005 and 2011, a total of 41 recipients recovered fromPneumocystispneumonia. Of these, 22 (53.7%) received secondary prophylaxis. None of the 41 recipients experienced recurrence ofPneumocystispneumonia during the follow-up, regardless of secondary prophylaxis.

scholarly journals Human T Cell Lymphotrophic Virus 1/2 in Solid Organ Transplantation

2013 ◽  
Vol 13 (s4) ◽  
pp. 355-360 ◽  
Author(s):  
D. R. Kaul ◽  
J. A. Davis ◽  
Keyword(s):  
T Cell ◽  
Organ Transplantation ◽  
Solid Organ Transplantation ◽  
Solid Organ ◽  
Human T Cell

Analysis of initial and follow-up CT findings in patients with invasive pulmonary aspergillosis after solid organ transplantation

2012 ◽  
Vol 67 (12) ◽  
pp. 1179-1186 ◽  
Author(s):  
C. Lim ◽  
J.B. Seo ◽  
S.-Y. Park ◽  
H.-J. Hwang ◽  
H.J. Lee ◽  
...  
Keyword(s):  
Organ Transplantation ◽  
Invasive Pulmonary Aspergillosis ◽  
Solid Organ Transplantation ◽  
Solid Organ ◽  
Pulmonary Aspergillosis ◽  
Ct Findings

scholarly journals Oridonin Prolongs the Survival of Mouse Cardiac Allografts by Attenuating the NF-κB/NLRP3 Pathway

2021 ◽  
Vol 12 ◽  
Author(s):  
Xiaoxiao Du ◽  
Weitao Que ◽  
Xin Hu ◽  
Xiao Yu ◽  
Wen-Zhi Guo ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
Organ Transplantation ◽  
Mrna Level ◽  
Solid Organ Transplantation ◽  
Solid Organ ◽  
Transplant Tolerance ◽  
Term Survival ◽  
Cardiac Allografts ◽  
Ifn Γ

BackgroundOridonin (Ori), the main bioactive ingredient of the natural anti-inflammatory herb Rabdosia rubescens, could be a covalent inhibitor of the NLRP3 inflammasome. Solid organ transplantation provides a life-saving optional therapy for patients with end-stage organ dysfunction. The long-term survival of solid organ transplantation remains restricted because of the possibility of rejection and the toxicity, infection, cardiovascular disease, and malignancy related to immunosuppressive (IS) drugs. However, the pathogenic mechanisms involved remain unclear. The ideal IS drugs to prevent allograft rejection have not been identified. Here, we investigated whether Ori could prolong the in vivo survival of completely mismatched cardiac allografts.MethodsThe cardiac transplantation models were conducted among three groups of mice from C57BL/6NCrSlc (B6/N) or C3H/HeNSlc (C3H) to C3H: the syngeneic and the allogeneic group, whose recipients were treated with vehicle of Ori, and the Ori treatment group, in which the recipients were transplanted hearts from MHC-I mismatched donors and treated with different dosages of Ori from post-operative day (POD) 0 to 7. Then, we investigated the effect of Ori on bone marrow-derived dendritic cell (BMDC) and allogeneic mixed lymphocyte reaction in vitro.ResultsOri with 3, 10, and 15 mg/kg Ori could prolong the survival (MST = 22.8, 49.2, and 65.3 days, respectively). We found that infiltrating CD8+ T cells and macrophages were decreased, and regulatory T cells (Tregs) were expanded in allografts on POD7. The mRNA level of IL-1β and IFN-γ of allografts was downregulated. Mechanistically, Ori-treated BMDCs suppressed T-cell proliferation and IFN-γ+CD4+ T-cell differentiation, along with the expansion of Tregs and IL-10+CD4+ T cells. Ori inhibited NOD, LRR-, and pyrin domain-containing protein 3 (NLRP3) expression; attenuated NF-κB and IκBα phosphorylation in LPS-activated BMDCs; downregulated NLRP3, Caspase-1, IL-1β, IL-18, and IFN-γ; and upregulated IL-10 expression.ConclusionsOur findings highlight the potential of Ori as a novel and natural IS agent to improve transplant tolerance. Ori could exert IS activity through decreasing IL-1β and IL-18 production and Th1 differentiation and proliferation and expanding Tregs via inhibiting the NF-κB/NLRP3 signaling pathway.

Sign in / Sign up

Export Citation Format

Share Document